| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09ca043d7e596facff1f44b746e2f4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2003-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b5ad677a79a57cceb2a31a7551d2630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579a55b0384cb108a8f12501a319ffa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7632b5a5bc7f8e845a24327d6ae84b93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3f7e0844684bc1b709d2098b416f29a |
| publicationDate |
2005-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20050058486-A |
| titleOfInvention |
Human antihuman interleukin-6 antibody and fragment of the antibody |
| abstract |
Interleukin 6 (IL-6) provides an agent that is effective in treating immune diseases in which it is involved. Humanized anti-human IL-6 antibodies and humanized anti-human IL-6 antibody fragments with high affinity for human IL-6 were obtained via phage antibody technology. Antibodies and antibody fragments are expected to be useful as agents for treating immune diseases or inflammation caused by IL-6. |
| priorityDate |
2002-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |